Supplementary Table S2. Types of cyclophosphamide schedule employed in the three different periods.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Periods of follow-up** | | | |
| **Overall** | **P1** | **P2** | **P3** |
| All schedules, N. | 258 | 49 | 95 | 114 |
| Oral cyclophosphamide, N. (%) | 182 (70.5) | 45 (91.8) | 69 (72.6) | 68 (59.6) |
| NIH schedule, N. (%) | 32 (12.4) | 4 (8.2) | 11 (11.6) | 17 (14.9) |
| Eurolupus schedule, N. (%) | 44 (17.1) | 0 | 15 (15.8) | 29 (25.4) |

P, period; P1: 1970-1985; P2: 1986-2001; P3: 2002-2016; NIH, National Institute of Health.